A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
NCT ID: NCT03516981
Last Updated: 2025-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
245 participants
INTERVENTIONAL
2018-10-01
2025-06-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
NCT02039674
Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
NCT02007070
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
NCT01840579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GEP low TMB low: Pembrolizumab + Quavonlimab
Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose (\[RP2D\], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
GEP low TMB low: Pembrolizumab + Favezelimab
Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
GEP low TMB low: Pembrolizumab + Lenvatinib
Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
GEP low TMB hi: Pembrolizumab + Quavonlimab
Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
GEP low TMB hi: Pembrolizumab + Favezelimab
Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
GEP low TMB hi: Pembrolizumab + Lenvatinib
Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
GEP hi TMB low: Pembrolizumab + Quavonlimab
Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
GEP hi TMB low: Pembrolizumab + Favezelimab
Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
GEP hi TMB low: Pembrolizumab + Lenvatinib
Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
GEP hi TMB hi: Pembrolizumab + Quavonlimab
Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
GEP hi TMB hi: Pembrolizumab + Favezelimab
Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
GEP hi TMB hi: Pembrolizumab + Lenvatinib
Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly accelerated fibrosarcoma- (B-Raf-) directed therapy is not indicated as primary therapy (documentation of absence of tumor activating EGFR mutations, B-Raf mutations, ALK gene rearrangements, and ROS1 gene rearrangements)
* Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology
* Male participants must agree to use contraception during the treatment period and for ≥120 days, after the last dose of study treatment and refrain from donating sperm during this period. Male participants with pregnant partners must agree to use a condom
* Female participants eligible to participate if not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow contraceptive guidance during the treatment period and for ≥120 days after the last dose of study treatment
* Provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
* Has adequate organ function
Exclusion Criteria
* Prolongation of QTc interval to \>480 milliseconds (ms)
* Has symptomatic ascites or pleural effusion
* Has had an allogenic tissue/solid organ transplant
* WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatment
* Has not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy, or has had major surgery within 3 weeks prior to first dose of study intervention
* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula, gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
* Radiographic evidence of major blood vessel invasion/infiltration
* Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
* Has received prior systemic chemotherapy treatment for metastatic/recurrent NSCLC
* Has current NSCLC disease that can be treated with curative intent with surgical resection, localized radiotherapy, or chemoradiation
* Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical resection)
* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor
* Has received previous treatment with another agent targeting the Lymphocyte-activation gene 3 (LAG-3) receptor
* Has received previous treatment with another agent targeting vascular endothelial growth factor (VEGF) or the VEGF receptor
* Has received prior anticancer therapy including investigational agents within 4 weeks prior to randomization
* Has received prior radiotherapy within 2 weeks of start of study treatment or received lung radiation therapy of \>30 Gy within 6 months prior to the first dose of study intervention
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study treatment
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab, favezelimab, or lenvatinib and/or any of its excipients
* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
* Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection
* Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days (females and males) after the last dose of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates, PC- HAL ( Site 8001)
Tempe, Arizona, United States
University of California Davis Comprehensive Cancer Center ( Site 0137)
Sacramento, California, United States
University of California San Francisco ( Site 0111)
San Francisco, California, United States
UCLA Hematology/Oncology -Santa Monica ( Site 0108)
Santa Monica, California, United States
Yale University School of Medicine ( Site 0100)
New Haven, Connecticut, United States
Mayo Clinic Florida ( Site 0115)
Jacksonville, Florida, United States
University of Maryland ( Site 0136)
Baltimore, Maryland, United States
Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117)
Rochester, Minnesota, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112)
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center ( Site 0113)
New York, New York, United States
Weill Cornell Medical College ( Site 0138)
New York, New York, United States
Oncology Hematology Care ( Site 8005)
Cincinnati, Ohio, United States
University of Pennsylvania ( Site 0132)
Philadelphia, Pennsylvania, United States
UPMC Cancer Center/Hillman Cancer Center ( Site 0104)
Pittsburgh, Pennsylvania, United States
Texas Oncology-Memorial City ( Site 8006)
Houston, Texas, United States
Texas Oncology-Tyler ( Site 8003)
Tyler, Texas, United States
Emily Couric Clinical Cancer Center ( Site 0134)
Charlottesville, Virginia, United States
Northwest Cancer Specialists, P.C. ( Site 8000)
Vancouver, Washington, United States
University of Wisconsin- Madison Carbone Cancer Center ( Site 0130)
Madison, Wisconsin, United States
Blacktown Hospital Western Sydney Local Health District ( Site 0200)
Blacktown, New South Wales, Australia
Gallipoli Medical Research Foundation ( Site 0202)
Brisbane, Queensland, Australia
Fiona Stanley Hospital ( Site 0201)
Murdoch, Western Australia, Australia
The Ottawa Hospital ( Site 0306)
Ottawa, Ontario, Canada
Sunnybrook Health Science Centre ( Site 0304)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0309)
Toronto, Ontario, Canada
CIUSSS du Saguenay-Lac-St-Jean ( Site 0305)
Chicoutimi, Quebec, Canada
Jewish General Hospital ( Site 0307)
Montreal, Quebec, Canada
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0310)
Montreal, Quebec, Canada
Prince of Wales Hospital ( Site 1801)
Hong Kong, , Hong Kong
Queen Mary Hospital ( Site 1800)
Hong Kong, , Hong Kong
St James Hospital ( Site 2200)
Dublin, , Ireland
Mid Western Cancer Centre ( Site 2201)
Limerick, , Ireland
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702)
Meldola, Emilia-Romagna, Italy
Istituto Clinico Humanitas Research Hospital ( Site 0700)
Rozzano, Lombardy, Italy
AOU San Luigi Gonzaga di Orbassano ( Site 0707)
Orbassano, Torino, Italy
AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701)
Legnago, Verona, Italy
Azienda Ospedaliera Papardo ( Site 0706)
Messina, , Italy
Seconda Universita degli Studi di Napoli ( Site 0704)
Napoli, , Italy
Fondazione Policlinico Universitario A. Gemelli ( Site 0703)
Roma, , Italy
Azienda Ospedaliera Universitaria Senese ( Site 0705)
Siena, , Italy
National Cancer Center Hospital ( Site 2001)
Tokyo, , Japan
The Cancer Institute Hospital of JFCR ( Site 2000)
Tokyo, , Japan
MED-POLONIA Sp. z o.o. ( Site 0907)
Poznan, Greater Poland Voivodeship, Poland
Dolnoslaskie Centrum Onkologii. ( Site 0993)
Wroclaw, Lower Silesian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, Poland
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003)
Ufa, Baskortostan, Respublika, Russia
The Loginov Moscow Clinical Scientific Center ( Site 1008)
Moscow, Moscow, Russia
N.N. Blokhin NMRCO ( Site 1000)
Moscow, Moscow, Russia
Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site
Omsk, Omsk Oblast, Russia
SBHI Leningrad Regional Clinical Hospital ( Site 1001)
Saint Petersburg, Sankt-Peterburg, Russia
St Petersburg City Clinical Oncology Dispensary ( Site 1002)
Saint Petersburg, Sankt-Peterburg, Russia
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005)
Kazan', Tatarstan, Respublika, Russia
National Cancer Centre Singapore ( Site 1900)
Singapore, Central Singapore, Singapore
National University Hospital ( Site 1901)
Singapore, South West, Singapore
MPOC ( Site 2310)
Groenkloof Pretoria, Gauteng, South Africa
Wits Clinical Research ( Site 2313)
Parktown-Johannesburg, Gauteng, South Africa
Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315)
Pretoria, Gauteng, South Africa
Sandton Oncology Medical Group PTY LTD ( Site 2316)
Sandton, Gauteng, South Africa
Vaal Triangle Oncology Centre ( Site 2314)
Vereeniging, Gauteng, South Africa
Umhlanga Oncolgy Center ( Site 2311)
Umhlanga, KwaZulu-Natal, South Africa
Cape Town Oncology Trials Pty Ltd ( Site 2312)
Kraaifontein, Western Cape, South Africa
Seoul National University Bundang Hospital ( Site 0803)
Seongnam-si, Kyonggi-do, South Korea
Asan Medical Center ( Site 0801)
Songpa-gu, Seoul, South Korea
Seoul National University Hospital ( Site 0800)
Seoul, , South Korea
Severance Hospital Yonsei University Health System ( Site 0802)
Seoul, , South Korea
Samsung Medical Center ( Site 0805)
Seoul, , South Korea
Hospital General Universitari Vall d Hebron ( Site 1100)
Barcelona, , Spain
Hospital Universitario Ramon y Cajal ( Site 1101)
Madrid, , Spain
Hospital Universitario 12 de Octubre ( Site 1102)
Madrid, , Spain
Kantonsspital St. Gallen ( Site 2102)
Saint Gallen, Canton of Aargau, Switzerland
Universitaetsspital Basel ( Site 2104)
Basel, Canton of Basel-City, Switzerland
Hopitaux Universitaires de Geneve HUG ( Site 2106)
Geneva, Canton of Geneva, Switzerland
Universitaetsspital Zuerich ( Site 2100)
Zurich, Canton of Zurich, Switzerland
Kantonsspital Graubuenden ( Site 2103)
Chur, Kanton Graubünden, Switzerland
Kaohsiung Chang Gung Memorial Hospital ( Site 1203)
Kaohsiung City, , Taiwan
National Cheng Kung University Hospital ( Site 1202)
Tainan City, , Taiwan
National Taiwan University Hospital ( Site 1200)
Taipei, , Taiwan
Taipei Veterans General Hospital ( Site 1204)
Taipei, , Taiwan
Cambridge University Hospitals NHS Trust ( Site 1306)
Cambridge, Cambridgeshire, United Kingdom
University College London Hospital NHS Foundation Trust ( Site 1308)
London, London, City of, United Kingdom
Derriford Hospital ( Site 1301)
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med. 2023 Jul;29(7):1718-1727. doi: 10.1038/s41591-023-02385-6. Epub 2023 Jul 10.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-495
Identifier Type: OTHER
Identifier Source: secondary_id
194621
Identifier Type: REGISTRY
Identifier Source: secondary_id
KEYNOTE-495
Identifier Type: OTHER
Identifier Source: secondary_id
2022-500990-16-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2017-003134-85
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-495
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.